Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
Trials May 21, 2024 Chiranth Bhagavan, Paul Glue, Will Evans et al. 7 citations
A clinical trial will test whether MDMA-assisted therapy can reduce anxiety and depression in people with advanced-stage cancer. Up to 32 participants will be randomly assigned to receive either 120 mg of MDMA (with an optional 60 mg supplement) or a low dose of methylphenidate as a psychoactive control, each combined with therapeutic support sessions. The study will track mood, anxiety, quality of life, and other measures for up to 12 months. This research aims to establish the safety and effectiveness of a novel treatment for mental suffering in patients with life-threatening illness.